On December 10, 2019, Canada, Mexico, and the United States
formally agreed to amend the successor to NAFTA, officially known
as CUSMA (short for the Canada-U.S.-Mexico Agreement) in Canada but
popularly referred to as USMCA following the American acronym. Our
firm's comprehensive review of the amendments can be found
here. This blog focuses on changes affecting biologic drugs and
patents.
CUSMA was first published in an agreed form on October 1, 2018.
The version released on December 10, 2019 removes a number of key
biologic drug and patent-related provisions that were agreed to in
principle last year, as we wrote about
here. As a result, under this revised USMCA, Canada will not be
required to change its domestic patent or pharmaceutical IP
regimes.